Article
Management of Transfusion-Related Iron Overload in Patients With Myelodysplastic Syndromes
Anemia is a common symptom for patients with myelodysplastic syndromes (MDS), a spectrum of hematopoietic malignancies characterized by ineffective hematopoiesis; 90% of these patients will become transfusion dependent (TD). Because of the closed nature of iron metabolism, the repeated input of packed red blood cells during transfusions inevitably leads to iron overload. Iron overload can cause iron-related toxicity as well as end-organ damage from iron deposition in tissues. Studies have shown that patients with MDS who are TD have shorter overall survival, shorter leukemia-free survival, and higher healthcare costs compared with patients who are not TD, suggesting that iron overload has a significant clinical and economic impact. Iron chelation therapy can bind and eliminate free iron from the body. Although studies in genetic anemias have shown improved clinical outcomes, clinical trials with patients with MDS are ongoing. Because iron chelation therapy can be toxic, the risks, benefits, and therapy-related costs must be weighed for each patient.
Jump to a section
References
Agarwal, M. B. (2010). Deferasirox: Oral, once daily iron chelator—An expert opinion. Indian Journal of Pediatrics, 77, 185-191. doi:10.1007/s12098-010-0030-4
Andrews, N. (2005). Iron metabolism. In N. Andrews, C. Breymann, C. Gasche, & ITO Staff (Eds.), ITO textbook—Iron therapy in various settings. Retrieved from http://www.irontherapy.org/a.php3?d=iron-metabolism-56&a=ITO-Textbook-Chapter-1:-Iron-Metabolism-4233
Armand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., … Antin, J. H. (2007). Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood, 109, 4586-4588. doi:10.1182/blood-2006-10-054924
Cappellini, M. D. (2008). Long-term efficacy and safety of deferasirox. Blood Reviews, 22(Suppl. 2), S35-S41. doi:10.1016/S0268-960X(08)70007-9
Cappellini, M. D., Bejaoui, M., Agaoglu, L., Canatan, D., Capra, M., Cohen, A., … Aydinok, Y. (2011). Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up. Blood, 118, 884-893. doi:10.1182/blood-2010-11-316646
Cermak, J., Jonasova, A., Vondrakova, J., Walterova, L., Hochova, I., Siskova, M., & Neuwirtova, R. (2011). Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin, 35, 217-227. doi:10.3109/03630269.2011.578515
Cermak, J., Kacirkova, P., Mikulenkova, D., & Michalova, K. (2009). Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leukemia Research, 33, 1469-1474. doi:10.1016/j.leukres.2009.06.033
ClinicalTrials.gov. (2011). Myelodysplastic syndromes (MDS) event free survival with iron chelation therapy study (TELESTO). Retrieved from http://www.clinicaltrials.gov/ct2/show/NCT00940602
Fausel, C. A. (2010). Iron chelation therapy in myelodysplastic syndromes. American Journal of Health-System Pharmacy, 67(7, Suppl. 2), S10-S14. doi:10.2146/ajhp090654
Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G. J., Mittelman, M., … Hellström-Lindberg, E. (2009). RBC transfusion independence and safety profile of lenalidomide 5 or 10 mg in patients with low- or int-1 risk MDS with del5q: Results from a randomized phase II trial (MDS-004) [Abstract 944]. Retrieved from http://ash.confex.com/ash/2009/webprogram/Paper21430.html
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., … International Vidaza High-Risk MDS Survival Study Group. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomized, open-label, phase III study. Lancet Oncology, 10, 223-232. doi:10.1016/S1470-2045(09)70003-8
Garcia-Manero, G. (2011). Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 86, 490-498. doi:10.1002/ajh.22047
Garcia-Manero, G., Shan, J., Faderl, S., Cortes, J., Ravandi, F., Borthakur, G., … Kantarjian, H. (2008). A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia, 22, 538-543. doi:10.1038/sj.leu.2405070
Gattermann, N., & Rachmilewitz, E. A. (2011). Iron overload in MDS-pathophysiology, diagnosis, and complications. Annals of Hematology, 90, 1-10. doi:10.1007/s00277-010-1091-1
Gattermann, N., Schmid, M., Porta, M. D., Taylor, K., Seymour, J. F., Habr, D., … Rose, C. (2008). Efficacy and safety of deferasirox (Exjade®) during one year of treatment in transfusion-dependent patients with myelodysplastic syndromes: Results from EPIC trial [Abstract 633]. Blood, 112, 235-236.
Goldberg, S. L., Chen, E., Corral, M., Guo, A., Mody-Patel, N., Pecora, A. L., & Laouri, M. (2010). Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology, 28, 2847-2852. doi:10.1200/JCO.2009.25.2395
Greenberg, P., Tuechler, H., Schanz, J., Sole, F., Bennett, J. M., Garcia-Manero, G., … Haase, D. (2011). Revised International Prognostic Scoring System (IPSS-R), developed by the International Working Group for Prognosis in MDS (IWG-PM) [Abstract 14]. Leukemia Research, 35(Suppl. 1), S6.
Harvey, R. D. (2010). Myelodysplastic syndromes and the role of iron overload. American Journal of Health-System Pharmacy, 67(7, Suppl. 2), S3-S9. doi:10.2146/ajhp090645
Hedley, B. D., Allan, A. L., & Xenocostas, A. (2011). The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clinical Cancer Research, 17, 6373-6380. doi:10.1158/1078-0432.CCR-10-2577
Heise, C., Carter, T., Schafer, P., & Chopra, R. (2010). Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Reviews of Anticancer Therapy, 10, 1663-1672.
Hershko, C. (2005). Treating iron overload: The state of the art. Seminars in Hematology, 42(2, Suppl. 1), S2-S4.
Jabbour, E., Kantarjian, H. M., Koller, C., & Taher, A. (2008). Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer, 112, 1089-1095. doi:10.1002/cncr.23280
Koptyra, M., Falinski, R., Nowicki, M. O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M., … Skorski, T. (2006). BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood, 108, 319-327. doi:10.1182/blood-2005-07-2815
Kurtin, S. (2011). Current approaches to the diagnosis and management of myelodysplastic syndromes. Journal of the Advanced Practitioner in Oncology, 2(Suppl. 2), 7-18.
Kurtin, S. E. (2007). Myelodysplastic syndromes: Diagnosis, treatment planning, and clinical management. Oncology (Williston Park), 21(11, Suppl. Nurse Ed.), 41-48.
Kurtin, S. E., & Demakos, E. P. (2010). An update on the treatment of myelodysplastic syndromes [Online exclusive]. Clinical Journal of Oncology Nursing, 14, E24-E39. doi:10.1188/10.CJON.E24-E39
Leitch, H. A. (2011a). Controversies surrounding iron chelation therapy for MDS. Blood Reviews, 25, 17-31. doi:10.1016/j.blre.2010.09.003
Leitch, H. A. (2011b). Optimizing therapy for iron overload in the myelodysplastic syndromes: Recent developments. Drugs, 71, 155-177. doi:10.2165/11585280-000000000-00000
Leitch, H. A., Leger, C. S., Goodman, T. A., Wong, K. K., Wong, D. H. C., Ramadan, K. M., … Vickars, L. M. (2008). Improved survival in patients with myelodysplastic syndromes receiving iron chelation therapy. Clinical Leukemia, 2, 205-211.
Leitch, H. A., & Vickars, L. M. (2009). Supportive care and chelation therapy in MDS: Are we saving lives or just lowering iron? Hematology American Society of Hematology Education Program, 664-672. doi:10.1182/asheducation-2009.1.664
Lipschitz, D. A., Cook, J. D., & Finch, C. A. (1974). A clinical evaluation of serum ferritin as an index of iron stores. New England Journal of Medicine, 290, 1213-1216. doi:10.1056/NEJM197405302902201
List, A. F. (2010). Iron overload in myelodysplastic syndromes: Diagnosis and management. Cancer Control, 17(Suppl.), 2-8.
Lübbert, M., Suciu, S., Baila, L., Ruter, B. H., Platzbecker, U., Giagounidis, A., … Wijermans, P. W. (2011). Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 29, 1987-1996. doi:10.1200/JCO.2010.30.9245
Malcovati, L., Della Porta, M. G., & Cazzola, M. (2006). Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica, 91, 1588-1590.
Malcovati, L., Della Porta, M. G., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., … Cazzola, M. (2005). Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. Journal of Clinical Oncology, 23, 7594-7603. doi:10.1200/JCO.2005.01.7038
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., … Cazzola, M. (2007). Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology, 25, 3503-3510. doi:10.1200/JCO.2006.08.5696
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., … Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: A systematic review and economic evaluation. Health Technology Assessment, 13, iii-iv, ix-xi, 1-121. doi:10.3310/hta13010
Messa, E., Cilloni, D., & Saglio, G. (2010). Iron chelation therapy in myelodysplastic syndromes. Retrieved from http://www.hindawi.com/journals/ah/2010/756289/
Naka, K., Muraguchi, T., Hoshii, T., & Hirao, A. (2008). Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxidants and Redox Signaling, 10, 1883-1894. doi:10.1089/ars.2008.2114
National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes [v.2.2011]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf
Nemeth, E. (2010). Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Retrieved from http://www.hindawi.com/journals/ah/2010/750643/
Neufeld, E. J. (2006). Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood, 107, 3436-3441. doi:10.1182/blood-2006-02-002394
Neufeld, E. J. (2010). Update on iron chelators in thalassemia. Retrieved from http://asheducationbook.hematologylibrary.org/content/2010/1/451.full
Neukirchen, J., Hildebrandt, B., Kuendgen, A., Nachtkamp, K., Haas, R., Gattermann, N., & Germing, U. (2011). Restratification of IPSS risk groups according to the WPSS identifies patients with myelodysplastic syndromes (MDS) at higher risk [Abstract 107]. Leukemia Research, 35(Suppl. 1), S124.
Nimer, S. D. (2008). Myelodysplastic syndromes. Blood, 111, 4841-4851. doi:10.1182/blood-2007-08-078139
Ning, B., Liu, G., Liu, Y., Su, X., Anderson, G. J., Zheng, X., … Nie, G. (2011). 5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (fech) genes. Journal of Biological Chemistry, 286, 37196-37206. doi:10.1074/jbc.M111.258129
Novartis Pharmaceuticals. (2007). Desferal® (deferoxamine mesylate) [Prescribing information]. Retrieved from http://www.pharma.us.novartis.com/product/pi/pdf/desferal.pdf
Novartis Pharmaceuticals. (2011). Exjade® (deferasirox) [Prescribing information]. Retrieved from http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf
Ozment, C. P., & Turi, J. L. (2009). Iron overload following red blood cell transfusion and its impact on disease severity. Biochimica et Biophysica Acta, 1790, 694-701. doi:10.1016/j.bbagen.2008.09.010
Payne, K. A., Rofail, D., Baladi, J. F., Viala, M., Abetz, L., Desrosiers, M. P., … Proskorovsky, I. (2008). Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in Therapy, 25, 725-742.
Pharmaceutical Management Agency. (2010). Deferiprone listing approved. Retrieved from http://www.pharmac.govt.nz/2010/09/10/2010-09-10%20Deferiprone%20listing%20notification.pdf
Porter, J., Galanello, R., Saglio, G., Neufeld, E. J., Vichinsky, E., Cappellini, M. D., … Rose, C. (2008). Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A one-year prospective study. European Journal of Haematology, 80, 168-176. doi:10.1111/j.1600-0609.2007.00985.x
Pullarkat, V. (2009). Objectives of iron chelation therapy in myelodysplastic syndromes: More than meets the eye? Blood, 114, 5251-5255. doi:10.1182/blood-2009-07-234062
Rassool, F. V., Gaymes, T. J., Omidvar, N., Brady, N., Beurlet, S., Pla, M., … Padua, R. A. (2007). Reactive oxygen species, DNA damage, and error-prone repair: A model for genomic instability with progression in myeloid leukemia? Cancer Research, 67, 8762-8771.
Santini, V., Girelli, D., Sanna, A., Martinelli, N., Duca, L., Campostrini, N., … Cappellini, M. D. (2011). Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PloS One, 6, e23109. doi:10.1371/journal.pone.0023109
Sanz, G., Nomdedeu, B., Such, E., Bernal, T., Belkaid, M., Ardanaz, M. T., … Cervera, J. (2008). Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [Abstract 640]. Blood, 112, 238-239.
Sekeres, M. A. (2011). Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. Journal of the National Comprehensive Cancer Network, 9, 57-63.
Sekeres, M. A., Schoonen, W. M., Kantarjian, H., List, A., Fryzek, J., Paquette, R., & Maciejewski, J. P. (2008). Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. Journal of the National Cancer Institute, 100, 1542-1551. doi:10.1093/jnci/djn349
Shander, A., & Sweeney, J. D. (2009). Overview of current treatment regimens in iron chelation therapy. Touch Briefings—U. S. Hematology, 2, 56-59.
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., … Holland, J. F. (2002). Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. Journal of Clinical Oncology, 20, 2429-2440.
Sloand, E. M., & Barrett, A. J. (2010). Immunosuppression for myelodysplastic syndrome: How bench to bedside to bench research led to success. Hematology Oncology Clinics of North America, 24, 331-341. doi:10.1016/j.hoc.2010.02.009
Steensma, D. P. (2011). The role of iron chelation therapy for patients with myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network, 9, 65-75.
Stumpf, J. L. (2007). Deferasirox. American Journal of Health-System Pharmacy, 64, 606-616. doi:10.2146/ajhp060405
Takatoku, M., Uchiyama, T., Okamoto, S., Kanakura, Y., Sawada, K., Tomonaga, M., … Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes. (2007). Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. European Journal of Haematology, 78, 487-494. doi:10.1111/j.1600-0609.2007.00842.x
U. S. Food and Drug Administration. (2011). FDA approves ferriprox to treat patients with excess iron in the body. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
Wrighting, D. M., & Andrews, N. C. (2008). Iron homeostasis and erythropoiesis. In J. J. Bieker (Ed.), Red cell development (pp. 141-167). London, England: Academic Press.
Yoo, C. B., & Jones, P. A. (2006). Epigenetic therapy of cancer: Past, present, and future. Nature Reviews Drug Discovery, 5, 37-50.